Celgene International Sárl (CELG) Release: Study to Evaluate Dose and Schedule for Oral Epigenetic Therapy CC-486 in Lower-Risk MDS Presented at American Society of Hematology  
12/10/2012 10:17:44 AM

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data from a phase I study of oral, epigenetic therapy CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes (MDS) was presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, GA.